New combo attack on stubborn cancers shows promise in early trial
NCT ID NCT03728361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants will receive both drugs intravenously and by mouth. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and temozolomide (Temodar)
What this could lead to
If it works, this combination could offer a new treatment option for patients with hard-to-treat small-cell lung cancer or advanced neuroendocrine tumors.
What could go wrong
This is a phase II trial with only 55 participants, so results are preliminary. The combination may cause significant side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center-COHORT 1
Columbus, Ohio, 43210, United States
-
Ohio State University Comprehensive Cancer Center-COHORT 2
Columbus, Ohio, 43210, United States